Please use this identifier to cite or link to this item:
|Title:||Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.|
|Authors:||Parakh, Sagun;Nguyen, Rebecca;Opie, Jacinta M;Andrews, Miles C|
|Affiliation:||Dermatology Unit, Austin Health, Heidelberg, Victoria, Australia|
Medical Oncology Unit, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
La Trobe University School of Cancer Medicine, Melbourne, Vic., Australia
|Citation:||The Australasian journal of dermatology 2017; 58(3): e109-e112|
|Abstract:||Dermatological toxicity is one of the most commonly reported immune-related adverse events in patients receiving checkpoint inhibitor immunotherapy. We report the gradual development of a widespread bullous pemphigoid-like reaction in a metastatic melanoma patient 8 months after commencing treatment with the programmed-death-1 (PD-1) inhibitor pembrolizumab, requiring prolonged corticosteroid therapy. This case highlights the potential for insidious and late development of severe cutaneous toxicity following PD-1 inhibitor therapy and suggests that even prolonged immunosuppression may not necessarily compromise the efficacy of PD-1 inhibition in advanced melanoma.|
programmed death-1 inhibition
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.